In the recent STEP-HFpEF study in patients with HFpEF and obesity, treatment with the GLP-1 RA semaglutide for one year led to greater reductions in symptoms and physical limitations, greater improvements in exercise function, and greater weight loss than the placebo [17]. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.